Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Masaki Kajita"'
Autor:
Shoji Fukushima, Masaki Kajita, Naoya Hashimoto, Akira Okada, Hiroji Iwata, Akimitsu Maeda, Masataka Sawaki, Hiromichi Ebi, Kei Irie, Hitoshi Ando
Publikováno v:
Investigational New Drugs. 39:272-277
Purpose The CKD4/6 inhibitor abemaciclib is related to adverse events such as hematological toxicity and increase in serum creatinine levels associated with abemaciclib pharmacokinetics. Increase in serum creatinine levels is considered a result of c
Autor:
Hitoshi Ando, Hiroya Taniguchi, Shoji Fukushima, Masaki Kajita, Masahiro Aoki, Shigenori Kadowaki, Ayako Hasegawa, Akimitsu Maeda, Masahiro Tajika, Kazuhide Inaguma, Akio Fujimura, Kei Muro, Kei Irie
Publikováno v:
Cancer Chemotherapy and Pharmacology. 83:107-113
The ability of predicting severe adverse reactions caused by regorafenib is important. We evaluated regorafenib concentrations for adverse reaction risks and assessed the relevance of laboratory values and gene polymorphisms. A total of 28 Japanese c
Autor:
Shigenori Kadowaki, Masaki Kajita, Yukiya Narita, Motoo Nomura, Yoshitsugu Horio, Ikue Haegawa, Akimitsu Maeda, Chisa Asano, Tatsuya Yoshida, Hiroya Taniguchi, Isao Oze, Kei Muro, Azusa Komori, Takashi Ura, Akiyoshi Mizutani
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 12:254-258
Aim To investigate the efficacy and safety of olanzapine in combination with palonosetron and dexamethasone for patients receiving cisplatin (≥50 mg/m2), because this antiemetic therapy has not been sufficiently examined in patients receiving cispl
Publikováno v:
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 41:701-704
Autor:
Akimitsu, Maeda, Takashi, Ura, Chisa, Asano, Ikue, Haegawa, Motoo, Nomura, Azusa, Komori, Yukiya, Narita, Hiroya, Taniguchi, Shigenori, Kadowaki, Kei, Muro, Yoshitsugu, Horio, Tatsuya, Yoshida, Isao, Oze, Masaki, Kajita, Akiyoshi, Mizutani
Publikováno v:
Asia-Pacific journal of clinical oncology. 12(3)
To investigate the efficacy and safety of olanzapine in combination with palonosetron and dexamethasone for patients receiving cisplatin (≥50 mg/m(2) ), because this antiemetic therapy has not been sufficiently examined in patients receiving cispla